1. Home
  2. ARBK vs IMAB Comparison

ARBK vs IMAB Comparison

Compare ARBK & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARBK
  • IMAB
  • Stock Information
  • Founded
  • ARBK 2017
  • IMAB 2014
  • Country
  • ARBK United Kingdom
  • IMAB United States
  • Employees
  • ARBK N/A
  • IMAB N/A
  • Industry
  • ARBK Finance: Consumer Services
  • IMAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • ARBK Finance
  • IMAB Health Care
  • Exchange
  • ARBK Nasdaq
  • IMAB Nasdaq
  • Market Cap
  • ARBK 20.1M
  • IMAB 200.9M
  • IPO Year
  • ARBK 2021
  • IMAB 2020
  • Fundamental
  • Price
  • ARBK $0.37
  • IMAB $2.45
  • Analyst Decision
  • ARBK Hold
  • IMAB Strong Buy
  • Analyst Count
  • ARBK 1
  • IMAB 2
  • Target Price
  • ARBK N/A
  • IMAB $6.00
  • AVG Volume (30 Days)
  • ARBK 557.3K
  • IMAB 1.2M
  • Earning Date
  • ARBK 08-27-2025
  • IMAB 05-15-2025
  • Dividend Yield
  • ARBK N/A
  • IMAB N/A
  • EPS Growth
  • ARBK N/A
  • IMAB N/A
  • EPS
  • ARBK N/A
  • IMAB N/A
  • Revenue
  • ARBK $47,017,000.00
  • IMAB N/A
  • Revenue This Year
  • ARBK $183.90
  • IMAB N/A
  • Revenue Next Year
  • ARBK $26.78
  • IMAB N/A
  • P/E Ratio
  • ARBK N/A
  • IMAB N/A
  • Revenue Growth
  • ARBK N/A
  • IMAB N/A
  • 52 Week Low
  • ARBK $0.15
  • IMAB $0.60
  • 52 Week High
  • ARBK $1.99
  • IMAB $3.08
  • Technical
  • Relative Strength Index (RSI)
  • ARBK 46.08
  • IMAB 50.05
  • Support Level
  • ARBK $0.35
  • IMAB $2.35
  • Resistance Level
  • ARBK $0.39
  • IMAB $2.59
  • Average True Range (ATR)
  • ARBK 0.03
  • IMAB 0.35
  • MACD
  • ARBK -0.00
  • IMAB -0.06
  • Stochastic Oscillator
  • ARBK 22.22
  • IMAB 1.86

About ARBK Argo Blockchain plc

Argo Blockchain PLC is a data center business that provides a powerful and efficient platform for cryptocurrency mining operations. The company has operations in strategic locations in North America.

About IMAB I-MAB

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

Share on Social Networks: